Gilead, Carna Biosciences announce research and development collaboration
Gilead and Carna Biosciences announced that the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna's proprietary lipid kinase drug discovery platform. Under the terms of the license agreement, Gilead will license from Carna worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target. In connection with this agreement, Carna will receive an upfront payment of $20M and is eligible to receive up to an additional $450M in potential milestone payments upon achievement of certain development and commercial milestones. Carna will also receive royalties on future net sales. Under the collaboration, Gilead will also have exclusive access to Carna's proprietary lipid kinase drug discovery platform.